Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic event(s). Conventional imaging (T1 and T2 weighted magnetic resonance imaging) has little to offer in the way of diagnosis of mental health conditions such as PTSD and there is currently no objective diagnostic test available. Magnetic resonance spectroscopy (MRS) allows for non-invasive measurement of metabolites and neurochemicals in the brain using a conventional MRI scanner and offers the potential to predict, diagnose and monitor PTSD. This systematic review summarises the results of 24 MRS studies, performed between 1998 and 2017, to measure neurochemical differences, occurring as a consequence of PTSD. The most consistent finding in subjects with PTSD is lower N-acetylaspartate levels in the hippocampus and anterior cingulate cortex, with and without atrophic change. More recent studies, using more advanced techniques and modern hardware, have shown evidence of glutamatergic dysfunction and differences in gamma-aminobutyric acid levels in the brain of patients with PTSD. Conflicting results have been reported in choline-containing metabolites and there is emerging evidence of glutathione being affected. Myo-inositol and creatine are unchanged in the majority of studies.
Introduction
Posttraumatic stress disorder (PTSD) is a trauma and stressor-related disorder that results in complex somatic, cognitive, affective and behavioural effects, after exposure to traumatic event(s). PTSD is precipitated by a number of factors, including exposure to actual or threatened death or serious injury or a response to intense fear, helplessness or horror. PTSD is characterised by persistent re-experiencing of the traumatic event; avoidance of stimuli related to the trauma; and hyperarousal for at least one month post trauma (American Psychiatric Association, 1994), leading to significant psychosocial impairment for patients. PTSD is common in the general and military populations with an estimated 12-month prevalence of 5.2% vs. 8.3%, respectively (McFarlane et al., 2010) .
In vivo neuro proton magnetic resonance spectroscopy (MRS) provides a non-invasive measurement of metabolites in the brain using a conventional magnetic resonance imaging (MRI) scanner at a field strength of 1.5 or 3 T. In vivo MRS can measure differences in parenchymal metabolism in both the healthy and diseased brain (Mountford et al., 2010) and has the potential to provide biomarkers for psychiatric disease, which often has no characteristic findings on conventional T1 and T2 weighted structural MRI (Foerster et al., 2012; Murray et al., 2014) . Up to 35 signals from metabolites, lipids, and macro-molecules can be measured using one dimensional (1D) neuro MRS at 3 T (Provencher, 2001). Commonly used 1D MRS pulse sequences, include Point-RESolved Spectroscopy (PRESS) and Stimulated Echo Acquisition Mode (STEAM). Shown below in Fig. 1 is a typical 1D neuro MRS spectrum (3T using a 64-channel head coil) from a healthy human brain labelled with the most commonly measured metabolites. MRS has the potential to shed further information on the pathogenesis and mechanisms behind PTSD, particularly when state of the art scanners are employed, which measure neurotransmitters such as gamma-aminobutyric acid (GABA), aspartate (Asp) and glutamate (Glu) non-invasively. This will further advance knowledge gained from other neuroimaging techniques such as functional magnetic resonance imaging (fMRI) and diffusion-weighted imaging (DWI). Additionally, in vivo neuro MRS is a promising technique that may help to predict patients at risk for PTSD and to non-invasively diagnose and monitor PTSD.
In this review, we synthesize previous work utilising proton MRS to characterise metabolic differences in the brain of patients with PTSD. Also, we give researchers a broader background on key MRS metabolites and brain regions implicated in the pathogenesis of PTSD that will help inform research findings and conclusions. Finally, we aim to determine if certain metabolites correlate with clinical variables, to identify possible MRS biomarkers of disease severity. We conclude with https://doi.org/10.1016/j.pscychresns.2018.07.001 Received 13 February 2018; Received in revised form 18 July 2018; Accepted 19 July 2018
